Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Boston Scientific to Acquire Nalu Medical for $533M, Expanding Neuromodulation Portfolio

Boston Scientific to Acquire Nalu Medical for $533M, Expanding Neuromodulation Portfolio

Boston Scientific has announced its agreement to acquire Nalu Medical, a private company specializing in neurostimulation technology for chronic pain management. The deal, valued at $533 million for the remaining equity not already owned by Boston Scientific, marks a significant expansion of the company's neuromodulation portfolio and reinforces its commitment to advanced pain relief solutions.

NoahAI News10/21/2025
FDA Approves Glaukos' Epioxa for Rare Eye Disorder Keratoconus

FDA Approves Glaukos' Epioxa for Rare Eye Disorder Keratoconus

The U.S. Food and Drug Administration (FDA) has granted approval to Glaukos Corporation for Epioxa, a novel treatment for keratoconus, a rare and potentially blinding eye disorder. This breakthrough therapy offers an incision-free alternative to traditional corneal cross-linking procedures, potentially revolutionizing treatment options for patients suffering from this debilitating condition.

NoahAI News10/21/2025
BioNTech Halts Further Development of Cancer Vaccine in Advanced Melanoma Setting

BioNTech Halts Further Development of Cancer Vaccine in Advanced Melanoma Setting

BioNTech, the German biotechnology company known for its mRNA technology, has announced it will not proceed with further development of its BNT111 cancer vaccine candidate in a specific late-stage refractory melanoma setting. This decision, revealed by a company spokesperson, aligns with BioNTech's strategy to focus on other programs from its FixVac mRNA platform.

NoahAI News10/21/2025
Mark Cuban's Cost Plus Drugs to Partner with TrumpRx, Signaling Shift in Prescription Drug Landscape

Mark Cuban's Cost Plus Drugs to Partner with TrumpRx, Signaling Shift in Prescription Drug Landscape

In a significant development for the pharmaceutical industry, Mark Cuban's Cost Plus Drugs has announced a partnership with TrumpRx, the upcoming direct-to-consumer prescription drug website initiated by the Trump administration. This collaboration marks a potential turning point in efforts to increase drug price transparency and reduce costs for American consumers.

NoahAI News10/21/2025
Daiichi Sankyo and Merck Advance Promising Ovarian Cancer ADC to Phase 3 Trial

Daiichi Sankyo and Merck Advance Promising Ovarian Cancer ADC to Phase 3 Trial

Daiichi Sankyo and Merck & Co. have reported encouraging phase 2 data for their antibody-drug conjugate (ADC) raludotatug deruxtecan (R-DXd) in ovarian cancer, paving the way for the treatment's advancement to a pivotal phase 3 trial. The results, presented at the 2025 European Society for Medical Oncology (ESMO) Congress, demonstrate the potential of this novel therapy in addressing the unmet needs of patients with recurrent, platinum-resistant ovarian cancer.

NoahAI News10/21/2025
AstraZeneca and Daiichi's Datroway Shows Promise in Hard-to-Treat Breast Cancer

AstraZeneca and Daiichi's Datroway Shows Promise in Hard-to-Treat Breast Cancer

AstraZeneca and Daiichi Sankyo's antibody-drug conjugate, Datroway, has demonstrated significant efficacy in a large clinical trial focused on aggressive, hard-to-treat breast cancer. The drug extended overall survival and progression-free survival in patients with inoperable metastatic triple-negative breast cancer for whom immunotherapy is not an option.

NoahAI News10/21/2025
CVS Health Ventures Leads $25M Funding Round for Obesity Care Startup Knownwell

CVS Health Ventures Leads $25M Funding Round for Obesity Care Startup Knownwell

Knownwell, a weight-inclusive primary care and metabolic health company, has secured $25 million in a funding round led by CVS Health Ventures. The investment highlights the growing focus on comprehensive obesity care models in the healthcare industry.

NoahAI News10/21/2025
Roche's Gazyva Secures FDA Approval for Lupus Nephritis, Expanding Treatment Options

Roche's Gazyva Secures FDA Approval for Lupus Nephritis, Expanding Treatment Options

Roche's long-standing oncology drug Gazyva (obinutuzumab) has received FDA approval for the treatment of adults with active lupus nephritis, marking a significant expansion of its therapeutic applications. This development comes as the lupus treatment landscape prepares for a potential shake-up, with Gazyva now positioned to compete in a market dominated by GSK's Benlysta.

NoahAI News10/21/2025
Summit's Dual-Acting Drug Shows Promise in Lung Cancer Trial, Sparking Industry Excitement and Debate

Summit's Dual-Acting Drug Shows Promise in Lung Cancer Trial, Sparking Industry Excitement and Debate

Summit Therapeutics and Akeso's dual-acting lung cancer drug ivonescimab has demonstrated significant efficacy in a closely watched Phase 3 trial, potentially reshaping first-line treatment regimens for advanced non-small cell lung cancer (NSCLC). The HARMONi-6 trial, conducted in Chinese patients, showed that ivonescimab combined with chemotherapy significantly delayed disease progression compared to the immunotherapy Tevimbra and chemotherapy.

NoahAI News10/21/2025
Roche Advances Eye Disease Drug Despite Mixed Phase 3 Results

Roche Advances Eye Disease Drug Despite Mixed Phase 3 Results

Roche, the Swiss pharmaceutical giant, is pushing forward with its plans to seek regulatory approval for vamikibart, an innovative eye disease drug, despite encountering mixed results in its latest phase 3 clinical trials. The company's determination to proceed highlights the complex landscape of drug development and the challenges faced by researchers in bringing new treatments to market.

NoahAI News10/21/2025
Exelixis Shares Drop as Colorectal Cancer Trial Results Fall Short of Expectations

Exelixis Shares Drop as Colorectal Cancer Trial Results Fall Short of Expectations

Exelixis, a prominent biotechnology company, faced a significant setback as its shares plummeted by over 10% following the release of data from a pivotal clinical trial. The STELLAR-303 study, which tested the experimental drug zanzalintinib in combination with Tecentriq for metastatic colorectal cancer, yielded results that failed to meet investor expectations.

NoahAI News10/21/2025
Ōura Pursues FDA Clearance for Blood Pressure Feature in Smart Ring

Ōura Pursues FDA Clearance for Blood Pressure Feature in Smart Ring

Ōura, a prominent player in the wearable technology market, has announced its intention to seek Food and Drug Administration (FDA) clearance for a blood pressure monitoring feature in its smart rings. This move marks a significant step in the company's journey from consumer devices to clinical applications, potentially revolutionizing personal health monitoring.

NoahAI News10/21/2025
«1...161718...67»